Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors CLIO-8221 is the first program from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results